101421-74-3 Usage
Uses
Used in Pharmaceutical Drug Development:
Quinazolin-8-amine is used as a pharmaceutical candidate for the treatment of various diseases, including cancer, inflammation, and neurological disorders. Its therapeutic potential is attributed to its unique chemical structure and properties, which allow it to interact with specific biological targets and modulate cellular processes.
Used in Organic Synthesis:
Quinazolin-8-amine serves as a building block in organic synthesis for the production of other compounds. Its versatile chemical properties enable it to be incorporated into various synthetic pathways, leading to the creation of novel molecules with potential applications in various fields, such as pharmaceuticals, agrochemicals, and materials science.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, quinazolin-8-amine is utilized for its potential to be developed into new drugs with improved efficacy and selectivity. Its unique structure allows for the design of targeted therapies that can specifically address the underlying causes of diseases, leading to more effective treatments with fewer side effects.
Used in Drug Discovery:
Quinazolin-8-amine plays a crucial role in drug discovery, where it is used as a starting point for the development of new therapeutic agents. Its chemical properties and potential interactions with biological targets make it an attractive candidate for further research and optimization, with the aim of discovering novel drugs with improved pharmacological profiles.
Check Digit Verification of cas no
The CAS Registry Mumber 101421-74-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,1,4,2 and 1 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 101421-74:
(8*1)+(7*0)+(6*1)+(5*4)+(4*2)+(3*1)+(2*7)+(1*4)=63
63 % 10 = 3
So 101421-74-3 is a valid CAS Registry Number.
InChI:InChI=1/C8H7N3/c9-7-3-1-2-6-4-10-5-11-8(6)7/h1-5H,9H2
101421-74-3Relevant articles and documents
Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain; Structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaliue, and cinnoline moieties
Gomtsyan, Arthur,Bayburt, Erol K.,Schmidt, Robert G.,Guo, Zhu Zheng,Perner, Richard J.,Didomenico, Stanley,Koenig, John R.,Turner, Sean,Jinkerson, Tammie,Drizin, Irene,Hannick, Steven M.,Macri, Bryan S.,McDonald, Heath A.,Honore, Prisca,Wismer, Carol T.,Marsh, Kennan C.,Wetter, Jill,Stewart, Kent D.,Oie, Tetsuro,Jarvis, Michael F.,Surowy, Carol S.,Faltynek, Connie R.,Lee, Chih-Hung
, p. 744 - 752 (2007/10/03)
Novel transient receptor potential vanilloid 1 (TRPV1) receptor antagonists with various bicyclic heteroaromatic pharmacophores were synthesized, and their in vitro activity in blocking capsaicin activation of TRPV1 was assessed. On the basis of the contribution of these pharmacophores to the in vitro potency, they were ranked in the order of 5-isoquinoline > 8-quinoline = 8-quinazoline > 8-isoquinoline ≥ cinnoline ≈ phthalazine ≈ quinoxaline ≈ 5-quinoline. The 5-isoquinoline-containing compound 14a (hTRPV1 IC50 = 4 nM) exhibited 46% oral bioavailability and in vivo activity in animal models of visceral and inflammatory pain. Pharmacokinetic and pharmacological properties of 14a are substantial improvements over the profile of the high-throughput screening hit 1 (hTRPV1 IC50 = 22 nM), which was not efficacious in animal pain models and was not orally bioavailable.
UREA COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN
-
Page 20-21, (2010/02/06)
Certain compounds of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, P, P', n, p, q, r and s are as defined in the specification, a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds in medicine.
